4F2Mab Biosimilar – Anti-ganglioside GD2, SFRP1, SLC3A2 mAb – Research Grade from ProteoGenix; catalogue PX-TA1073; research use only.
Know who made it. See the evidence. Buy through one marketplace.
4F2Mab Biosimilar is a monoclonal antibody (mAb) that targets three specific proteins: ganglioside GD2, secreted frizzled-related protein 1 (SFRP1), and solute carrier family 3 member 2 (SLC3A2). This biosimilar has been developed as a potential therapeutic option for various diseases, including cancer and autoimmune disorders. In this article, we will discuss the structure, activity, and potential applications of 4F2Mab Biosimilar in detail.
4F2Mab Biosimilar is a recombinant humanized IgG1 monoclonal antibody that is produced in mammalian cells. It consists of two heavy chains and two light chains, each containing variable and constant regions. The variable regions are responsible for binding to the targeted proteins, while the constant regions determine the effector functions of the antibody.
4F2Mab Biosimilar has a high binding affinity for its three target proteins, making it a potent therapeutic agent. It specifically binds to ganglioside GD2, which is overexpressed in various types of cancer cells, including neuroblastoma and melanoma. By binding to GD2, 4F2Mab Biosimilar can block the growth and survival of these cancer cells, making it a promising anti- cancer therapy.
In addition to GD2, 4F2Mab Biosimilar also targets SFRP1 and SLC3A2. SFRP1 is a secreted protein that plays a role in regulating the Wnt signaling pathway, which is involved in cell proliferation and differentiation. By binding to SFRP1, 4F2Mab Biosimilar can modulate the Wnt signaling pathway and potentially inhibit the growth of cancer cells. SLC3A2, also known as CD98, is a transmembrane protein that is involved in cell adhesion and nutrient transport. By targeting SLC3A2, 4F2Mab Biosimilar can disrupt the functions of cancer cells and potentially induce their death.
4F2Mab Biosimilar has shown promising results in preclinical studies as a potential therapy for various types of cancer, including neuroblastoma, melanoma, and breast cancer. It has also shown potential in treating autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, by targeting SFRP1 and SLC3A2.
Furthermore, 4F2Mab Biosimilar has the potential to be used in combination with other therapies, such as chemotherapy and radiation, to enhance their efficacy. This is due to its ability to target multiple proteins that are involved in cancer growth and survival.
In conclusion, 4F2Mab Biosimilar is a promising monoclonal antibody that targets three specific proteins involved in cancer and autoimmune disorders. Its high binding affinity and ability to disrupt key cellular functions make it a potential therapeutic option for various diseases. Further clinical studies are needed to fully understand the potential of this biosimilar and its applications in the field of medicine.
ProteoGenix catalogue number PX-TA1073. For research use only.
Target: 4F2Mab Biosimilar – Anti-ganglioside GD2, SFRP1, SLC3A2 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB, Flow Cyt.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| 4F2Mab Biosimilar – Anti-ganglioside GD2, SFRP1, SLC3A2 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
